Physician profile
Manish Sheth
NPI 1205832730
$23,937.22
in general payments reported to CMS, 2019-2025
68 companies · $412 in 2025
The $412 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,347 · 2020: $4,011 · 2021: $1,429 · 2022: $4,074 · 2023: $2,397 · 2024: $3,267 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,118 · Consulting Fee: $2,580 · Education: $378.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,118.43 |
| Consulting Fee | $2,580.00 |
| Education | $377.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,222.67 | 2019-2025 | Epkinly, Venclexta |
| Incyte Corporation | $2,804.08 | 2019-2024 | Jakafi, Monjuvi, Pemazyre |
| Amgen INC. | $2,573.54 | 2019-2023 | Lumakras, Xgeva, Vectibix |
| Novartis Pharmaceuticals Corporation | $2,142.32 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,874.09 | 2019-2023 | |
| Janssen Biotech, INC. | $1,761.11 | 2019-2024 | Rybrevant, Darzalex, Tecvayli |
| Regeneron Healthcare Solutions, INC. | $733.61 | 2019-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $526.75 | 2019-2023 | Imbruvica, Epkinly |
| Astrazeneca Pharmaceuticals LP | $489.84 | 2019-2025 | Datroway, Enhertu, Lynparza |
| E.R. Squibb & Sons, L.L.C. | $457.49 | 2019-2023 | Opdivo, Camzyos |
| Pfizer INC. | $421.16 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $373.85 | 2021-2023 | Keytruda, Lynparza, Welireg |
| Genentech USA, INC. | $329.83 | 2019-2023 | Venclexta, Columvi, Lunsumio |
| Rigel Pharmaceuticals, INC. | $319.97 | 2019-2024 | Rezlidhia, Tavalisse |
| Takeda Pharmaceuticals U.S.A., INC. | $284.36 | 2019-2023 | Iclusig, Alunbrig, Ninlaro |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manish Sheth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.